Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1326-1334 , December 2006

Comparison of Reduced-Intensity and Conventional Myeloablative Regimens for Allogeneic Transplantation in Non-Hodgkin’s Lymphoma

  • Roberto Rodriguez

      Affiliations

    • Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California
    • Corresponding Author InformationCorrespondence and reprint requests: Roberto Rodriguez, MD, Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, 1500 E Duarte Road, MOB 3001, Duarte, CA 91001.
    • ,
  • Auayporn Nademanee

      Affiliations

    • Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California
    • ,
  • Nora Ruel

      Affiliations

    • Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California
    • ,
  • Eileen Smith

      Affiliations

    • Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California
    • ,
  • Amrita Krishnan

      Affiliations

    • Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California
    • ,
  • Leslie Popplewell

      Affiliations

    • Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California
    • ,
  • Jasmine Zain

      Affiliations

    • Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California
    • ,
  • Kathy Patane

      Affiliations

    • Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California
    • ,
  • Neil Kogut

      Affiliations

    • Southern California Permanente Bone Marrow Transplant Program, Duarte, California
    • ,
  • Ryotaro Nakamura

      Affiliations

    • Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California
    • ,
  • Clarence Sarkodee-Adoo

      Affiliations

    • City of Hope Good Samaritan Transplant Program, Phoenix, Arizona
    • ,
  • Stephen J. Forman

      Affiliations

    • Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, California

Received 5 December 2005 ,Accepted 20 August 2006.

References 

  1. Ringden O, Labopin M, Frassoni F, et al. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Bone Marrow Transplant. 1999;24:389–396
  2. Tsai T, Goodman S, Saez R, et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant. 1997;20:859–863
  3. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531–4536
  4. Porter DL, Luger SM, Duffy KM, et al. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:230–238
  5. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. National Cancer Institute–sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112–2135
  6. Cheson BD, Horning SJ, Coiffier B, et al. NCI Sponsored International Working Group Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol. 1999;17:1244
  7. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141–1154
  8. R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2003;
  9. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509
  10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  11. Mehta CR, Patel NR. A network algorithm for performing Fisher’s exact test in rXc contingency tables. J Am Stat Assoc. 1983;78:427–434
  12. Champlin R, Khouri I, Kornblau S, et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative preparative regimens and induction of graft-versus-malignancy. Curr Opin Oncol. 1999;11:87–95
  13. Clift RA, Radich J, Appelbaum FR, et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during the chronic phase of chronic myeloid leukemia. Blood. 1999;94:3960–3962
  14. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997;89:3055–3060
  15. de Lima M, Anagnostopoulos A, Munsell M, et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation. Blood. 2004;104:865–872
  16. Niederwieser D, Maris M, Shizuru JA, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620–1629
  17. Rodriguez R, Parker P, Nademanee A, et al. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies. Bone Marrow Transplant. 2004;33:1123–1129
  18. Morris E, Thomson K, Craddock C, et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin’s lymphoma. Blood. 2004;104:3865–3871
  19. Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood. 2002;100:4310–4316
  20. Norasetthada L, Maris MB, Sandmaier BM, et al. HLA-matched related (MRD) or unrelated (URD) non-myeloablative hematopoietic cell transplantation (HCT) for patients with refractory and relapsed aggressive non-Hodgkin’s lymphoma. [abstract] Blood. 2004;104:634a
  21. Dean RM, Fowler DH, Wilson WH, et al. Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin’s lymphoma. Biol Blood Marrow Transplant. 2005;11:593–599
  22. Staudt LM, Dave S. The biology of human lymphoid malignancies revealed by gene expression profiling. Adv Immunol. 2005;87:163–208

PII: S1083-8791(06)00579-9

doi: 10.1016/j.bbmt.2006.08.035

Biology of Blood and Marrow Transplantation
Volume 12, Issue 12 , Pages 1326-1334 , December 2006

Article Tools

* Image Usage & Resolution